Skip to content

Opening book details…

Can I read In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Escherichia coli , Klebsiella pneumoniae , Acinetobacter baumannii , and Pseudomonas aeruginosa Strains at a Tertiary Hospital in Korea on EtoBox?

In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Escherichia coli , Klebsiella pneumoniae , Acinetobacter baumannii , and Pseudomonas aeruginosa Strains at a Tertiary Hospital in Korea by Nguyen, Le (author);Park, Chul (author);Pinto, Naina (author);Lee, Hyunsook (author);Seo, Hyun (author);Vu, Thao (author);Mai, Hung (author);Pham, An (author);Jang, Eris (author);Cho, Young (author);Goglin, Karrie (author);Nguyen, Kevin (author);White, Richard (author);D’Souza, Roshan (author);Fouts, Derrick (author);Yong, Dongeun (author) is a Medicine article available to read on EtoBox.

What is In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Escherichia coli , Klebsiella pneumoniae , Acinetobacter baumannii , and Pseudomonas aeruginosa Strains at a Tertiary Hospital in Korea about?

The siderophore–antibiotic conjugate LCB10-0200 (a.k.a. GT-1) has been developed to combat multidrug-resistant Gram-negative bacteria. In this study, the in vitro activity of LCB10-0200 and LCB10-0200/avibactam (AVI) has been investigated against carbapenem-resistant __Escherichia coli__, __Klebsiella pneumoniae__, __Acinetobacter baumannii__, and __Pseudomonas aeruginosa__. Minimal inhibitory concentrations (MICs) of LCB10-0200, LCB10-0200/AVI, aztreonam, aztreonam/AVI, ceftazidime, ceftazidime/AVI, and meropenem were measured using the agar dilution method. Whole genome sequencing was performed using Illumina and the resistome was analyzed. LCB10-0200 displayed stronger activity than the comparator drugs in meropenem-resistant __E. coli__ and __K. pneumoniae__, and the addition of AVI enhanced the LCB10-0200 activity to MIC ≤ 0.12 mg/L for 90.5% of isolates. In contrast, whereas LCB10-0200 alone showed potent activity against meropenem-resistant __A. baumannii__ and __P. aeruginosa__ at MIC ≤ 4 mg/L for 84.3% of isolates, the combination with AVI did not improve its activity. LCB10-0200/AVI was active against CTX-M-, SHV-, CMY-, and KPC- producing __E. coli__ and __K. pneumoniae_

Who reads In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Escherichia coli , Klebsiella pneumoniae , Acinetobacter baumannii , and Pseudomonas aeruginosa Strains at a Tertiary Hospital in Korea?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Nguyen, Le (author);Park, Chul (author);Pinto, Naina (author);Lee, Hyunsook (author);Seo, Hyun (author);Vu, Thao (author);Mai, Hung (author);Pham, An (author);Jang, Eris (author);Cho, Young (author);Goglin, Karrie (author);Nguyen, Kevin (author);White, Richard (author);D’Souza, Roshan (author);Fouts, Derrick (author);Yong, Dongeun (author)
Publisher
MDPI AG
Published
2021
Language
EN
Field
Medicine (Life Sciences)

More by Nguyen, Le (author);Park, Chul (author);Pinto, Naina (author);Lee, Hyunsook (author);Seo, Hyun (author);Vu, Thao (author);Mai, Hung (author);Pham, An (author);Jang, Eris (author);Cho, Young (author);Goglin, Karrie (author);Nguyen, Kevin (author);White, Richard (author);D’Souza, Roshan (author);Fouts, Derrick (author);Yong, Dongeun (author)

Browse all works by Nguyen, Le (author);Park, Chul (author);Pinto, Naina (author);Lee, Hyunsook (author);Seo, Hyun (author);Vu, Thao (author);Mai, Hung (author);Pham, An (author);Jang, Eris (author);Cho, Young (author);Goglin, Karrie (author);Nguyen, Kevin (author);White, Richard (author);D’Souza, Roshan (author);Fouts, Derrick (author);Yong, Dongeun (author)